DSIP — 4mg

Delta Sleep-Inducing Peptide (DSIP) is a 9-amino acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 by the Schoenenberger–Monnier group at the University of Basel from cerebral venous blood of rabbits during electrically induced slow-wave sleep. Its discovery emerged from attempts to identify humoral factors that transfer sleep states across organisms, and early research demonstrated that administration to recipient animals produced increases in electroencephalographic delta-wave activity — the hallmark of deep, restorative sleep.

Unlike classical sleep-regulating neurotransmitters, DSIP does not act on GABAergic or adenosinergic pathways directly. Its mechanism is pleiotropic and not fully characterized: research has implicated it in modulation of corticotropin-releasing hormone (CRH) and the hypothalamic-pituitary-adrenal (HPA) axis, interaction with opioidergic signaling, and influence on circadian rhythm through effects on the suprachiasmatic nucleus. It also produces measurable effects on thyroid and growth hormone secretion in animal models, suggesting a broader neuroendocrine role beyond sleep regulation.

Research applications have extended well beyond the sleep-initiating effects that gave DSIP its name. Studies have examined its effects on chronic stress adaptation, withdrawal syndromes in animal models of opioid and alcohol dependence, pain threshold modulation, and post-traumatic and depressive-type behavioral endpoints. The peptide's extremely short plasma half-life (estimated in minutes) has been a persistent challenge for research translation, and its endogenous function remains debated — some investigators question whether it exists at physiologically relevant concentrations in human brain tissue. Despite these uncertainties, it remains an active subject of neurophysiological research, particularly in sleep architecture and HPA-axis studies.